Literature DB >> 12528884

Systemic thrombolytic therapy after recent abdominal aortic aneurysm repair: an absolute contraindication?

David G Cable1, Kenneth J Cherry.   

Abstract

Systemic thrombolysis in the early postoperative period can cause fatal hemorrhage. Systemic thrombolysis is often considered contraindicated after major vascular procedures; thus, experience with this scenario is limited. A 67-year-old man experienced massive pulmonary embolization after his abdominal aortic aneurysm was repaired with a bifurcated, woven Dacron graft. Because systemic thrombolysis was the only option for our patient's survival, he underwent this procedure with recombinant tis-sue-type plasminogen activator just 2 weeks after the Dacron graft repair of his abdominal aortic aneurysm. After clinical stabilization, abdominal and pelvic computed tomography showed no periprosthetic graft hemorrhage. The successful systemic thrombolysis suggests that this therapy may prove useful in extreme situations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12528884     DOI: 10.4065/78.1.99

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  3 in total

1.  Life-saving systemic thrombolysis in a patient with massive pulmonary embolism and a recent hemorrhagic cerebrovascular accident.

Authors:  Wendy Bottinor; Jeremy Turlington; Syed Raza; Charlotte S Roberts; Rajiv Malhotra; Ion S Jovin; Antonio Abbate
Journal:  Tex Heart Inst J       Date:  2014-04-01

2.  Acute arterial thrombosis after covered stent exclusion of bleeding mycotic pseudoaneurysm: treatment using catheter-directed thrombolysis.

Authors:  Sarah Palestrant; M Grace Knuttinen; Ron C Gaba; James T Bui; Charles A Owens
Journal:  Int J Vasc Med       Date:  2011-04-28

Review 3.  Management dilemmas in acute pulmonary embolism.

Authors:  Robin Condliffe; Charlie A Elliot; Rodney J Hughes; Judith Hurdman; Rhona M Maclean; Ian Sabroe; Joost J van Veen; David G Kiely
Journal:  Thorax       Date:  2013-12-16       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.